Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors
Open Access
- 30 April 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 17 (4) , e3000229
Abstract
Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are still required, especially during fulminant hepatitis outbreaks. A more in-depth understanding of the antigenic characteristics of HAV and the mechanisms of neutralization could aid in the development of rationally designed antiviral drugs targeting HAV. In this paper, 4 new antibodies—F4, F6, F7, and F9—are reported that potently neutralize HAV at 50% neutralizing concentration values (neut50) ranging from 0.1 nM to 0.85 nM. High-resolution cryo-electron microscopy (cryo-EM) structures of HAV bound to F4, F6, F7, and F9, together with results of our previous studies on R10 fragment of antigen binding (Fab)-HAV complex, shed light on the locations and nature of the epitopes recognized by the 5 neutralizing monoclonal antibodies (NAbs). All the epitopes locate within the same patch and are highly conserved. The key structure-activity correlates based on the antigenic sites have been established. Based on the structural data of the single conserved antigenic site and key structure-activity correlates, one promising drug candidate named golvatinib was identified by in silico docking studies. Cell-based antiviral assays confirmed that golvatinib is capable of blocking HAV infection effectively with a 50% inhibitory concentration (IC50) of approximately 1 μM. These results suggest that the single conserved antigenic site from complete HAV capsid is a good antiviral target and that golvatinib could function as a lead compound for anti-HAV drug development. Hepatitis A virus (HAV) is a unique, hepatotropic human picornavirus that infects approximately 1.5 million people annually and continues to cause mortality despite a successful vaccine. There are no licensed therapeutic drugs to date. Better knowledge of HAV antigenic features and neutralizing mechanisms will facilitate the development of HAV-targeting antiviral drugs. In this study, we report 4 potent HAV-specific neutralizing monoclonal antibodies (NAbs), together with our previous reported R10, that efficiently inhibit HAV infection by blocking attachment to the host cell. All 5 epitopes are located within the same patch and are highly conserved across 6 genotypes of human HAV, which suggests a single antigenic site for HAV, highlighting a prime target for structure-based drug design. Analysis of complexes with the 5 NAbs with varying neutralizing activities pinpointed key structure-activity correlates. By using a robust in silico docking method, one promising inhibitor named golvatinib was successfully identified from the DrugBank Database. In vitro assays confirmed its ability to block viral infection and revealed its neutralizing mechanism. Our approach could be useful in the design of effective drugs for picornavirus infections.Keywords
Funding Information
- Sichuan Province Foundation (2015JQO029)
- Strategic Priority Research Program (XDB29010000)
- the Key Programs of the Chinese Academy (KJZD-SW-L05)
- National Key Research and Development Program of China (2017YFC0840300)
- National Key Research and Development Program of China (2017YFA0505903)
- National Natural Science Foundation of China (31800145)
- National Natural Science Foundation of China (31570717)
- National Natural Science Foundation of China (31770186)
- National Natural Science Foundation of China (31370735)
- National Natural Science Foundation of China (31670737)
- Sichuan Province Foundation (2014KJT021-2014SZ)
- Foundation from Chengdu HI-TECH Industrial Development Zone (2016-XT00-00033-GX-01)
This publication has 57 references indexed in Scilit:
- RELION: Implementation of a Bayesian approach to cryo-EM structure determinationJournal of Structural Biology, 2012
- A plate-based high-throughput assay for virus stability and vaccine formulationJournal of Virological Methods, 2012
- Prevention of overfitting in cryo-EM structure determinationNature Methods, 2012
- Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular SimulationsThe Journal of Physical Chemistry B, 2008
- Interpretation of electron density with stereographic roadmap projectionsJournal of Structural Biology, 2007
- EMAN2: An extensible image processing suite for electron microscopyJournal of Structural Biology, 2007
- Automated electron microscope tomography using robust prediction of specimen movementsJournal of Structural Biology, 2005
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- EMAN: Semiautomated Software for High-Resolution Single-Particle ReconstructionsJournal of Structural Biology, 1999